GlassScriptPhysician profile
Sagar Naik
NPI 1245473297
$16,724.77
in general payments reported to CMS, 2019-2025
28 companies · $1,868 in 2025
The $1,868 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,672 · 2020: $339 · 2021: $313 · 2022: $470 · 2023: $11K · 2024: $886 · 2025: $1,868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $9,020 · Food and Beverage: $2,674 · Travel and Lodging: $2,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $9,020.00 |
| Food and Beverage | $2,673.68 |
| Travel and Lodging | $2,236.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,429.78 | 2023-2025 | Da Vinci Surgical System, Ion |
| Astrazeneca Pharmaceuticals LP | $1,456.60 | 2019-2025 | Fasenra, Tagrisso, Farxiga |
| Glaxosmithkline, LLC. | $464.25 | 2019-2024 | Nucala |
| Actelion Pharmaceuticals US, INC. | $365.17 | 2019-2020 | |
| Allergan, INC. | $244.65 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.37 | 2019-2020 | |
| United Therapeutics Corporation | $215.91 | 2019-2025 | Tyvaso |
| W. L. Gore & Associates, INC. | $187.55 | 2023 | Gore Excluder Aaa Endoprosthesis |
| Chiesi USA, INC. | $153.33 | 2019-2021 | |
| Abbvie INC. | $112.43 | 2022 | |
| Inari Medical, INC. | $110.29 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Mallinckrodt Enterprises LLC | $98.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $97.38 | 2019-2024 | Xarelto |
| Philips North America LLC | $91.70 | 2019-2023 | |
| La Jolla Pharmaceutical Company | $78.45 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $77.65 | 2019-2020 | |
| Grifols USA, LLC | $62.63 | 2019-2020 | |
| Mylan Specialty L.P. | $44.28 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $35.49 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.33 | 2020 | |
| Pfizer INC. | $22.34 | 2019-2021 | |
| Advanced Respiratory, INC | $21.31 | 2019 | |
| Genzyme Corporation | $20.52 | 2019 | |
| Genentech USA, INC. | $20.38 | 2019 | |
| Csl Behring | $20.00 | 2024 | Kcentra |
| Merck Sharp & Dohme LLC | $19.07 | 2023 | Recarbrio, Zerbaxa, Dificid |
| Electromed, INC. | $16.91 | 2019 | |
| Gilead Sciences, INC. | $13.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sagar Naik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.